PMID- 31241173
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200214
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
VI  - 58
IP  - 9
DP  - 2019 Sep
TI  - Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated 
      with imatinib.
PG  - 1098-1101
LID - 10.1111/ijd.14562 [doi]
AB  - OBJECTIVE: The aim of this study was to see the patterns of skin changes in 
      chronic myeloid leukemia (CML) in chronic phase treated with different doses of 
      imatinib. METHODS: This cross-sectional study was conducted in the Oncology 
      Department of Jinnah Hospital, Lahore, over a period of 6 months. Patients aged 
      7-70 years diagnosed either by fluorescence in situ hybridization (FISH) for 
      BCR-ABL or cytogenetics for Philadelphia (Ph) chromosomes and consuming different 
      doses of imatinib for the treatment of CML were randomly selected. Skin 
      manifestations were analyzed and recorded on a predesigned proforma by a 
      dermatologist. RESULTS: A total of 132 patients were enrolled; 65 male (49.24%) 
      and 67 female (50.75%). Periorbital edema was found in 48.5% of cases, and 
      hyperpigmentaion and melasma were found in 76.5% of cases. Pruritus was diagnosed 
      in 6.8% of cases, alopecia in 5.3% of cases, and photosensitivity in 43.9% of 
      cases. CONCLUSIONS: It was concluded that imatinib is associated with many 
      adverse cutaneous side effects which should be overcome or reduced by either 
      decreasing the duration of treatment with imatinib or switching to other 
      treatment options.
CI  - (c) 2019 International Society of Dermatology.
FAU - Khokar, Abbas
AU  - Khokar A
AD  - King Edward Medical University (KEMU)/Mayo Hospital, Lahore, Pakistan.
FAU - Malik, Uzma
AU  - Malik U
AD  - King Edward Medical University (KEMU)/Mayo Hospital, Lahore, Pakistan.
FAU - Butt, Ghazala
AU  - Butt G
AUID- ORCID: 0000-0002-3875-0961
AD  - King Edward Medical University (KEMU)/Mayo Hospital, Lahore, Pakistan.
FAU - Naumeri, Fatima
AU  - Naumeri F
AD  - Jefferson Joint School District 251, Lahore, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20190626
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (abl-bcr fusion protein, human)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects
MH  - Child
MH  - Cross-Sectional Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Eruptions/*epidemiology/etiology
MH  - Female
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Humans
MH  - Imatinib Mesylate/administration & dosage/*adverse effects
MH  - Leukemia, Myeloid, Chronic-Phase/*drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Pakistan/epidemiology
MH  - Philadelphia Chromosome
MH  - Protein Kinase Inhibitors/administration & dosage/*adverse effects
MH  - Time Factors
MH  - Young Adult
EDAT- 2019/06/27 06:00
MHDA- 2020/02/15 06:00
CRDT- 2019/06/27 06:00
PHST- 2019/02/11 00:00 [received]
PHST- 2019/04/17 00:00 [revised]
PHST- 2019/05/31 00:00 [accepted]
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2019/06/27 06:00 [entrez]
AID - 10.1111/ijd.14562 [doi]
PST - ppublish
SO  - Int J Dermatol. 2019 Sep;58(9):1098-1101. doi: 10.1111/ijd.14562. Epub 2019 Jun 
      26.